- Home
- HUIZ vs BIVI Comparison
HUIZ vs BIVI Comparison
Compare HUIZ & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- BIVI
- Stock Information
- Founded
- HUIZ 2006
- BIVI 2013
- Country
- HUIZ China
- BIVI United States
- Employees
- HUIZ N/A
- BIVI N/A
- Industry
- HUIZ Specialty Insurers
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- HUIZ Finance
- BIVI Health Care
- Exchange
- HUIZ Nasdaq
- BIVI Nasdaq
- Market Cap
- HUIZ 18.8M
- BIVI 18.6M
- IPO Year
- HUIZ 2020
- BIVI N/A
- Fundamental
- Price
- HUIZ $2.09
- BIVI $1.02
- Analyst Decision
- HUIZ Hold
- BIVI Strong Buy
- Analyst Count
- HUIZ 1
- BIVI 1
- Target Price
- HUIZ $2.30
- BIVI $30.00
- AVG Volume (30 Days)
- HUIZ 16.9K
- BIVI 194.8K
- Earning Date
- HUIZ 06-06-2025
- BIVI 05-12-2025
- Dividend Yield
- HUIZ N/A
- BIVI N/A
- EPS Growth
- HUIZ N/A
- BIVI N/A
- EPS
- HUIZ N/A
- BIVI N/A
- Revenue
- HUIZ $168,454,627.00
- BIVI N/A
- Revenue This Year
- HUIZ $11.94
- BIVI N/A
- Revenue Next Year
- HUIZ $8.15
- BIVI N/A
- P/E Ratio
- HUIZ N/A
- BIVI N/A
- Revenue Growth
- HUIZ 1.28
- BIVI N/A
- 52 Week Low
- HUIZ $1.50
- BIVI $0.62
- 52 Week High
- HUIZ $10.58
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- HUIZ 49.04
- BIVI 47.95
- Support Level
- HUIZ $2.04
- BIVI $1.00
- Resistance Level
- HUIZ $2.21
- BIVI $1.09
- Average True Range (ATR)
- HUIZ 0.10
- BIVI 0.07
- MACD
- HUIZ 0.01
- BIVI -0.01
- Stochastic Oscillator
- HUIZ 18.87
- BIVI 19.05
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies who cooperate with the company, who the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.